Search research articles
Contact Us
Filters
Showing results (151-160 of 160) with videos related to
Page
of 16
Sort By:
You have reached the last page of results.
This site can display upto 160 results.
Contemporary Clinical Trials
|
April 18, 2024
D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 years
Anna Turkova, Man K Chan, Cissy Kityo, et al.
The Lancet. HIV
|
August 4, 2023
Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation study
Kristina M Brooks, Jennifer J Kiser, Lauren Ziemba, et al.
The Lancet. HIV
|
May 11, 2020
Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial
Esaú C João, R Leavitt Morrison, David E Shapiro, et al.
Eclinicalmedicine
|
June 12, 2023
Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV - Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial
Alexandra Compagnucci, Man K Chan, Yacine Saïdi, et al.
Plos Medicine
|
August 14, 2013
Switching HIV treatment in adults based on CD4 count versus viral load monitoring: a randomized, non-inferiority trial in Thailand
Gonzague Jourdain, Sophie Le Cœur, Nicole Ngo-Giang-Huong, et al.
The New England Journal of Medicine
|
March 8, 2018
Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B
Gonzague Jourdain, Nicole Ngo-Giang-Huong, Linda Harrison, et al.
The New England Journal of Medicine
|
December 29, 2021
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children
Anna Turkova, Ellen White, Hilda A Mujuru, et al.
Nature Communications
|
May 10, 2024
Assessment of three antibiotic combination regimens against Gram-negative bacteria causing neonatal sepsis in low- and middle-income countries
Biljana Kakaraskoska Boceska, Tuba Vilken, Basil Britto Xavier, et al.
Archives of Disease in Childhood
|
August 26, 2019
Towards understanding global patterns of antimicrobial use and resistance in neonatal sepsis: insights from the NeoAMR network
Grace Li, Julia Anna Bielicki, A S M Nawshad Uddin Ahmed, et al.
Plos Medicine
|
June 8, 2023
Patterns of antibiotic use, pathogens, and prediction of mortality in hospitalized neonates and young infants with sepsis: A global neonatal sepsis observational cohort study (NeoOBS)
Neal J Russell, Wolfgang Stöhr, Nishad Plakkal, et al.
Page
of 16
Search research articles
Search
Showing results (151-160 of 160) with videos related to
Sort By:
Page
of 16
You have reached the last page of results.
This site can display upto 160 results.
Contemporary Clinical Trials
|
April 18, 2024
D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 years
Anna Turkova, Man K Chan, Cissy Kityo, et al.
The Lancet. HIV
|
August 4, 2023
Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation study
Kristina M Brooks, Jennifer J Kiser, Lauren Ziemba, et al.
The Lancet. HIV
|
May 11, 2020
Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial
Esaú C João, R Leavitt Morrison, David E Shapiro, et al.
Eclinicalmedicine
|
June 12, 2023
Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV - Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial
Alexandra Compagnucci, Man K Chan, Yacine Saïdi, et al.
Plos Medicine
|
August 14, 2013
Switching HIV treatment in adults based on CD4 count versus viral load monitoring: a randomized, non-inferiority trial in Thailand
Gonzague Jourdain, Sophie Le Cœur, Nicole Ngo-Giang-Huong, et al.
The New England Journal of Medicine
|
March 8, 2018
Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B
Gonzague Jourdain, Nicole Ngo-Giang-Huong, Linda Harrison, et al.
The New England Journal of Medicine
|
December 29, 2021
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children
Anna Turkova, Ellen White, Hilda A Mujuru, et al.
Nature Communications
|
May 10, 2024
Assessment of three antibiotic combination regimens against Gram-negative bacteria causing neonatal sepsis in low- and middle-income countries
Biljana Kakaraskoska Boceska, Tuba Vilken, Basil Britto Xavier, et al.
Archives of Disease in Childhood
|
August 26, 2019
Towards understanding global patterns of antimicrobial use and resistance in neonatal sepsis: insights from the NeoAMR network
Grace Li, Julia Anna Bielicki, A S M Nawshad Uddin Ahmed, et al.
Plos Medicine
|
June 8, 2023
Patterns of antibiotic use, pathogens, and prediction of mortality in hospitalized neonates and young infants with sepsis: A global neonatal sepsis observational cohort study (NeoOBS)
Neal J Russell, Wolfgang Stöhr, Nishad Plakkal, et al.
Page
of 16